InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,273.54
(
0.29%
)
Post# of 252302
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

theordore

Send PM Follow Ignore
Followers 0
Posts 24
Boards Moderated 0
Alias Born 07/25/2015

theordore

Re: None

Thursday, 08/13/2015 2:10:44 PM

Thursday, August 13, 2015 2:10:44 PM

Post# of 252302
After Praluent (REGN) and ETC-1002 (ESPR), are there other rival drugs for investors' interest in the cholesterol-reduction drug market? (I am excluding a long list of statin drugs already approved by FDA, assuming that Praluent and ETC-1002 are doing things inside the body that these older anti-cholesterol drugs failed to do. Is that right?) Thanks in advance.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up